PureCycle Technologies, Inc. (PCT) - 10-Q Summary for Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. PureCycle Technologies, Inc. is a Florida-based corporation commercializing patented dissolution recycling technology to convert waste polypropylene into PureFive™ resin. The company operates a commercial-scale facility in Ironton, Ohio, which is currently in the commissioning phase but not yet at full capacity. Management has concluded that the previous "substantial doubt" regarding the company's ability to continue as a going concern has been alleviated following a significant capital raise in June 2025.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $3.2 million | $0 |
| Net Loss | $(135.4) million | $(133.8) million |
| Operating Loss | $(83.3) million | $(78.9) million |
| Cash and Cash Equivalents (End of Period) | $284.1 million | $10.9 million |
| Total Debt (Gross) | $375.6 million | $346.6 million |
| Net Cash Used in Operating Activities | $(75.6) million | $(79.6) million |
| Net Cash Provided by Financing Activities | $355.6 million | $(223.3) million |
Note: The Net Loss for the six months ended June 30, 2025, includes a non-cash expense of $25.6 million related to the change in fair value of warrants.
Material Changes vs. Prior Period
- Liquidity Transformation: Cash and cash equivalents increased from $15.7 million at year-end 2024 to $284.1 million at June 30, 2025. This was driven primarily by the issuance of Series B Convertible Perpetual Preferred Stock, which generated approximately $300.0 million in gross proceeds.
- Revenue Recognition: The company reported $3.2 million in revenue for the six months ended June 30, 2025, compared to zero in the prior year period, marking the first year of meaningful operations and sales.
- Operating Expenses: Cost of operations increased by $9.9 million year-over-year, driven by a $3.7 million loss on disposal of fixed assets and higher production-related costs due to the ramp-up at the Ironton Facility.
- Warrant Liability: The change in fair value of warrants resulted in an expense of $25.6 million for the six months ended June 30, 2025, compared to $9.6 million in the prior year period.
Guidance, Outlook, and Risks
- Capital Raise and Growth Plans: Following the $300 million Series B Preferred Stock offering, PCT announced plans to construct a 130 million-pound facility in Thailand (operational mid-2027), a 130 million-pound facility in Antwerp, Belgium (operational 2028), and a 300 million-pound multi-line facility in Augusta, Georgia (operational 2029).
- Regulatory Progress: In July 2025, the company received an additional FDA Letter of No Objection (LNO), expanding the range of process conditions for PureFive™ resin and allowing use in a broader array of food contact applications.
- Going Concern: Management states that current financial projections support the ability to meet obligations for at least the next twelve months, removing the previous going concern qualification.
- Risks: Key risks include the ability to complete construction of new facilities on time and budget, regulatory compliance for food-grade applications, operational risks at the Ironton Facility, and the volatility of warrant liabilities impacting reported earnings.
Investor Verification Checklist
- Verify the operational status and commissioning timeline of the Ironton Facility, as full-scale commercial operations have not yet commenced.
- Review the terms of the Series B Convertible Perpetual Preferred Stock, specifically the 7% cumulative dividend rate and conversion mechanics.
- Assess the impact of the $146.8 million warrant liability on future earnings volatility.
- Monitor the progress of the Thailand and Belgium facility permitting and construction schedules.
- Confirm the status of the Denham-Blythe arbitration regarding the Ironton Facility construction, which involves claims of approximately $17.0 million.